6 Mar

Creative monetisation of de-prioritised IP is the next frontier for Big Pharma strategists

In their drive towards specialisation and prioritisation, larger life sciences companies risk neglecting some of their valuable IP assets, writes Adam Houldsworth. A greater focus on the creative monetisation of de-prioritised inventions could pay dividends

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth